Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of the study is to assess the safety of semagacestat in Alzheimer’s disease patients during 24 months of open-label treatment following completion of up to 21 months of active treatment in a double-blind registration study (LFAN or LFBC) through analysis of AEs, vital signs, laboratory evaluations, and electrocardiograms (ECGs).
Inclusion criteria
- Alzheimer's disease